We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

BIOMERIEUX

Designs, develops, manufactures and markets in vitro diagnostics systems used in clinical and industrial applications read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Cell-Free DNA Sequencing Confirms Myelodysplastic Syndrome Diagnosis

By LabMedica International staff writers
Posted on 25 Aug 2016
Print article
Image: The NucliSENS EasyMAG automated platform for total DNA extraction (Photo courtesy of BioMérieux).
Image: The NucliSENS EasyMAG automated platform for total DNA extraction (Photo courtesy of BioMérieux).
The use of next-generation sequencing (NGS) methods to analyze cell-free DNA (cf-DNA) in the blood of patients with myelodysplastic syndrome (MDS) yields more accurate results than the current standard approach of Sanger sequencing.

Myelodysplastic syndromes (MDSs) are a heterogeneous group of disorders, characterized by the presence of clonal neoplastic cells in bone marrow that lead to ineffective hematopoiesis and peripheral blood (PB) cytopenias. The major criteria for the diagnosis of MDS are the presence of peripheral cytopenia and dysplasia.

Scientists at the NeoGenomics Laboratories (Irvine, CA, USA) collected PB samples were collected from 16 patients confirmed to have MDS by bone marrow evaluation and from four age-matched normal controls. All patients had blasts of less than 5%. This included patients with refractory cytopenia with unilineage dysplasia, refractory cytopenia with multilineage dysplasia, and refractory anemia with ring sideroblasts (RARS). The team extracted cf-DNA from plasma and cellular DNA from PB cells.

Total nucleic acid was isolated from plasma using NucliSENS EasyMAG automated platform (BioMérieux, Marcy-l'Étoile, France). DNA was then quantified using Qubit 2.0 Fluorometer (Thermo Fisher Scientific, Waltham, MA, USA). NGS and Sanger Sequencing were performed for several specific genes. Polymerase chain reaction products were purified and sequenced in both forward and reverse directions using an ABI PRISM 3730XL Genetic Analyzer (Applied Biosystems, Foster City, CA, USA).

Upon deep sequencing of the plasma cf-DNA, all 16 patients showed at least one mutated gene, confirming the presence of an abnormal clone consistent with MDS. No abnormality was detected in any of the four samples from normal control individuals. Eight patients (50%) showed mutation in one gene and the remaining eight patients (50%) showed mutations in two or more genes. Five of the 16 patients (31%) showed mutations detected by NGS of cf-DNA, while Sanger sequencing of PB cellular DNA showed no evidence of mutation.

Garth D. Ehrlich, PhD, FAAAS, Editor-in-Chief of the journal where the study was published, said, “This is a remarkable finding that cell-free DNA provides a more sensitive assay for detecting cancer than does the traditional approach of analyzing cell-associated DNA.” The study was published on July 14, 2016, in the journal Genetic Testing and Molecular Biomarkers.

Related Links:
NeoGenomics Laboratories
BioMérieux
Thermo Fisher Scientific
Applied Biosystems
Gold Supplier
SARS-CoV-2 qRT-PCR IVD Reagent Kit
SARS-CoV-2 qRT-PCR Dx Kit (CE-IVD)
New
5-Part Differential Hematology Analyzer
Abacus 5
New
Automatic Biochemistry Analyzer
Falcon 260
New
5-Part Differential Hematology Analyzer
DxH 690T

Print article
IIR Middle East

Channels

Molecular Diagnostics

view channel
Image: The ultrarapid genome sequencing pipeline, indicating all processes from sample collection to a diagnosis. Vertically stacked processes are run in parallel (Photo courtesy of Stanford University)

Ultrarapid Nanopore Genome Sequencing in a Critical Care Setting

A genetic diagnosis can guide clinical management and improve prognosis in critically ill patients, and much effort has gone into developing methods that result in rapid, reliable results.... Read more

Hematology

view channel
Image: New one-step test screens for three rare genetic disorders simultaneously in newborns (Photo courtesy of Murdoch Children’s Research Institute)

New One-Step Test Screens for Three Rare Genetic Disorders Simultaneously In Newborns

A newly developed test to screen for three rare genetic disorders simultaneously in newborns was feasible, reliable and scalable, according to a new study. The research, led by the Murdoch Children’s... Read more

Industry

view channel
Illustration

Global Immunofluorescence Assay (IFA) Market to Surpass USD 4 Billion by 2028 Due to Growing Burden of Infectious Diseases

The global immunofluorescence assay (IFA) market is expected to reach USD 4.01 billion by 2028, driven by the increasing global healthcare burden of chronic and infectious diseases, rising application... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.